Frontiers in Immunology (Mar 2023)

Molecules promoting circulating clusters of cancer cells suggest novel therapeutic targets for treatment of metastatic cancers

  • Julian M. Rozenberg,
  • Anton A. Buzdin,
  • Anton A. Buzdin,
  • Anton A. Buzdin,
  • Anton A. Buzdin,
  • Tharaa Mohammad,
  • Olga A. Rakitina,
  • Dmitry A. Didych,
  • Victor V. Pleshkan,
  • Victor V. Pleshkan,
  • Irina V. Alekseenko,
  • Irina V. Alekseenko,
  • Irina V. Alekseenko

DOI
https://doi.org/10.3389/fimmu.2023.1099921
Journal volume & issue
Vol. 14

Abstract

Read online

Treatment of metastatic disease remains among the most challenging tasks in oncology. One of the early events that predicts a poor prognosis and precedes the development of metastasis is the occurrence of clusters of cancer cells in the blood flow. Moreover, the presence of heterogeneous clusters of cancerous and noncancerous cells in the circulation is even more dangerous. Review of pathological mechanisms and biological molecules directly involved in the formation and pathogenesis of the heterotypic circulating tumor cell (CTC) clusters revealed their common properties, which include increased adhesiveness, combined epithelial-mesenchymal phenotype, CTC-white blood cell interaction, and polyploidy. Several molecules involved in the heterotypic CTC interactions and their metastatic properties, including IL6R, CXCR4 and EPCAM, are targets of approved or experimental anticancer drugs. Accordingly, analysis of patient survival data from the published literature and public datasets revealed that the expression of several molecules affecting the formation of CTC clusters predicts patient survival in multiple cancer types. Thus, targeting of molecules involved in CTC heterotypic interactions might be a valuable strategy for the treatment of metastatic cancers.

Keywords